https://doi.org/10.1002/14651858.CD015391
Cochrane disclaims all liability and responsibility arising from any reliance placed on this supplementary material which has been supplied by the author(s). The above associated publication’s Author Licence will apply in respect of any supplemental materials published. How to cite the supplementary material is defined in the Cochrane policy.
Study name |
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) |
Methods |
|
Participants |
Inclusion Criteria
Exclusion Criteria
|
Interventions |
Details of intervention
Treatment details of control group (e.g. dose, route of administration)
|
Outcomes |
|
Starting date |
1 January 2021 |
Contact information |
covidout@umn.edu |
Notes |
|
Study name |
Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients |
Methods |
|
Participants |
Inclusion criteria
Exclusion criteria
|
Interventions |
Details of intervention
Treatment details of control group (e.g. dose, route of administration)
|
Outcomes |
|
Starting date |
18 January 2021 |
Contact information |
andrea.fekete@sigmadrugs.com |
Notes |
|
Study name |
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications |
Methods |
|
Participants |
Inclusion criteria
Exclusion criteria
|
Interventions |
Details of intervention
Treatment details of control group (e.g. dose, route of administration)
|
Outcomes |
|
Starting date |
13 May 2021 |
Contact information |
sybil.wilson@duke.edu, and april.ray@duke.edu |
Notes |
|
Study name |
Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community |
Methods |
|
Participants |
Inclusion criteria
Exclusion criteria
|
Interventions |
Details of intervention
Treatment details of control group (e.g. dose, route of administration)
|
Outcomes |
|
Starting date |
21 October 2021 |
Contact information |
Dhammika.L@chula.ac.th, Phatthranit.pha@mahidol.edu |
Notes |
|
Study name |
Effect of Combined Fluvoxamine with Favipiravir versus Favipiravir Monotherapy in Prevention of Clinical Deterioration among mild to moderate COVID-19 patients Monitoring by Telemedicine in Virtual Clinic |
Methods |
|
Participants |
Inclusion criteria
Exclusion criteria
|
Interventions |
Details of intervention
Treatment details of control group (e.g. dose, route of administration)
|
Outcomes |
|
Starting date |
16 June 2021 |
Contact information |
taweegrit.sir@pccms.ac.th. |
Notes |
|
COVID-19: Coronavirus Disease 2019; JAK: Janus Kinase; PCR: Polymerase Chain Reaction; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2